Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study

nork Gori, Stefania, Clavarezza, Matteo, Siena, Salvatore, Foglietta, Jennifer, Tarenzi, Emiliana, Giordano, Monica, Molino, Annamaria, Graiff, Claudio, Fusco, Vittorio, Alabiso, Oscar, Baldini, Editta, Gamucci, Teresa, Altavilla, Giuseppe, Dondi, Davide, Venturini, Marco
Argitaratua 2012

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

nork Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Caserta, Claudia, Fabi, Alessandra, Clavarezza, Matteo, Maiello, Evaristo, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Proietti, Emanuela, Agati, Raffaele, Eusebi, Vincenzo, Franceschi, Enrico
Argitaratua izan da Neuro Oncol (2016)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

nork Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Tosoni, Alicia, Eoli, Marica, Lombardi, Giuseppe, Clavarezza, Matteo, Paccapelo, Alexandro, Bartolini, Stefania, Cirillo, Luigi, Agati, Raffaele, Franceschi, Enrico
Argitaratua izan da Oncotarget (2017)

Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study

nork Clavarezza, Matteo, Bordonaro, Roberto, Daniele, Bruno, Ferrandina, Gabriella, Barni, Sandro, Turazza, Monica, Coati, Francesca, De Matteis, Andrea, De Placido, Sabino, Cognetti, Francesco, Olmeo, Nina Antonina, Carrozza, Francesco, Bruzzi, Paolo, Del Mastrol, Lucia
Argitaratua 2013

Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study

nork Clavarezza, Matteo, Bordonaro, Roberto, Daniele, Bruno, Ferrandina, Gabriella, Barni, Sandro, Turazza, Monica, Coati, Francesca, De Matteis, Andrea, De Placido, Sabino, Cognetti, Francesco, Olmeo, Nina Antonina, Carrozza, Francesco, Bruzzi, Paolo, Del Mastro, Lucia
Argitaratua 2013

Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study

nork Clavarezza, Matteo, Mustacchi, Giorgio, Casadei Gardini, Andrea, Del Mastro, Lucia, De Matteis, Andrea, Riccardi, Ferdinando, Adamo, Vincenzo, Aitini, Enrico, Amoroso, Domenico, Marchetti, Paolo, Gori, Stefania, Carrozza, Francesco, Maiello, Evaristo, Giotta, Francesco, Dondi, Davide, Venturini, Marco
Argitaratua 2012

AT-11 FINAL RESULTS FROM THE RANDOMIZED PHASE II TRIAL AVAREG (ML25739) WITH BEVACIZUMAB (BEV) OR FOTEMUSTINE (FTM) IN RECURRENT GBM

nork Brandes, Alba A., Finocchiaro, Gaetano, Zagonel, Vittorina, Reni, Michele, Fabi, Alessandra, Caserta, Claudia, Clavarezza, Matteo, Maiello, Evaristo, Cartenì, Giacomo, Rosti, Giovanni, Eoli, Marica, Lombardi, Giuseppe, Monteforte, Marta, Agati, Raffaele, Eusebi, Vincenzo, Galli, Anna, Doria, Simona, Franceschi, Enrico
Argitaratua 2014

NI-26 COMPARATIVE ANALYSIS OF THE RANO AND MACDONAD'S CRITERIA IN RECURRENT GLIOBLASTOMA TREATED IN THE RANDOMIZED PHASE II TRIAL AVAREG WITH BEVACIZUMAB OR FOTEMUSTINE.

nork Franceschi, Enrico, Agati, Raffaele, Finocchiaro, Gaetano, Zagonel, Vittorina, Fabi, Alessandra, Reni, Michele, Caserta, Claudia, Maiello, Evaristo, Cartenì, Giacomo, Clavarezza, Matteo, Rosti, Giovanni, Eoli, Marica, Lombardi, Giuseppe, Bacci, Antonella, Monteforte, Marta, Doria, Simona, Galli, Anna, Brandes, Alba A.
Argitaratua 2014

The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin...

nork Petrera, Marilena, Paleari, Laura, Clavarezza, Matteo, Puntoni, Matteo, Caviglia, Silvia, Briata, Irene Maria, Oppezzi, Massimo, Mislej, Eva Mihajlovic, Stabuc, Borut, Gnant, Michael, Bachleitner-Hofmann, Thomas, Roth, Wilfried, Scherer, Dominique, Haefeli, Walter-E., Ulrich, Cornelia M., DeCensi, Andrea
Argitaratua izan da BMC Cancer (2018)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer

nork Campora, Sara, Campazzi, Eleonora, Zanardi, Silvia, Puntoni, Matteo, Piccininno, Marco, Piccardo, Arnoldo, Shoushtari Zadeh Naseri, Mehrdad, Defferrari, Carlotta, Provinciali, Nicoletta, Petrera, Marilena, Marra, Domenico, Biscaldi, Ennio, Antonucci, Gian Carlo, Ricci, Damiano, Clavarezza, Matteo, Gennari, Alessandra, Gozza, Alberto, D'Amico, Mauro, Mori, Marco, DeCensi, Andrea
Argitaratua izan da Transl Oncol (2016)

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

nork Morano, Federica, Corallo, Salvatore, Lonardi, Sara, Raimondi, Alessandra, Cremolini, Chiara, Rimassa, Lorenza, Murialdo, Roberto, Zaniboni, Alberto, Sartore-Bianchi, Andrea, Tomasello, Gianluca, Racca, Patrizia, Clavarezza, Matteo, Adamo, Vincenzo, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Busico, Adele, Martinetti, Antonia, Palermo, Federica, Loupakis, Fotios, Milione, Massimo, Fucà, Giovanni, Di Bartolomeo, Maria, de Braud, Filippo, Pietrantonio, Filippo
Argitaratua izan da J Clin Oncol (2019)

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Tr...

nork Pietrantonio, Filippo, Morano, Federica, Corallo, Salvatore, Miceli, Rosalba, Lonardi, Sara, Raimondi, Alessandra, Cremolini, Chiara, Rimassa, Lorenza, Bergamo, Francesca, Sartore-Bianchi, Andrea, Tampellini, Marco, Racca, Patrizia, Clavarezza, Matteo, Berenato, Rosa, Caporale, Marta, Antista, Maria, Niger, Monica, Smiroldo, Valeria, Murialdo, Roberto, Zaniboni, Alberto, Adamo, Vincenzo, Tomasello, Gianluca, Giordano, Monica, Petrelli, Fausto, Longarini, Raffaella, Cinieri, Saverio, Falcone, Alfredo, Zagonel, Vittorina, Di Bartolomeo, Maria, de Braud, Filippo
Argitaratua izan da JAMA Oncol (2019)